This activity was originally presented at the 2022 ASHP Midyear Clinical Meeting & Exposition.
Program Description
Ovarian cancer is often termed a “silent killer” due to asymptomatic tumor growth, delayed symptom onset, and inadequate screening among women leading to advanced stage disease at presentation. While most women with advanced-stage epithelial ovarian cancer will have good response to initial systemic therapy, many will experience a recurrence of their disease and require additional treatment. Multiple studies have shown that poly (ADP-ribose) polymerase (PARP) inhibitors prolong survival in women receiving therapy in the maintenance and recurrent ovarian cancer settings without a substantial increase in adverse effects (AEs). However, their oral administration presents unique challenges in the management of toxicity and adherence monitoring. Pharmacists practicing in oncology clinics and health-system settings are central providers of comprehensive education to patients to explain nuances of therapy with PARP inhibitors, including how these medications work, administration techniques, which AEs to expect, available strategies to avoid AEs, and what potential drug-drug interactions may occur. Expert faculty will discuss patient cases and examine strategies to overcome potential barriers impacting treatment decisions, access to therapy, and medication adherence for patients with ovarian cancer receiving PARP inhibitors.
Target audience: Health-system and Oncology Pharmacists
Type of activity: Application
Release date: December 22, 2022
Expiration date: March 1, 2024
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Differentiate PARP inhibitors for the treatment of ovarian cancer by pharmacology, safety, and FDA-approved indications
- Apply guideline recommendations and drug therapy knowledge to individualize treatment selection for a patient with advanced or metastatic ovarian cancer
- Provide strategies to mitigate adverse effects associated with PARP inhibitors in the treatment of advanced or metastatic ovarian cancer
Jason J. Bergsbaken, PharmD, MBA, BCOP
Pharmacy Coordinator, Regional Oncology Services
Program Director, PGY2 Oncology Pharmacy Residency
UW Health
Clinical Assistant Professor
University of Wisconsin-Madison School of Pharmacy
Madison, Wisconsin
Amy L. Indorf, PharmD, BCOP
Clinical Oncology Pharmacist
UW Medicine/Fred Hutchinson Cancer Center
Seattle, Washington
Thomasina Morris, RPh, MHA, BCOP
Clinical Pharmacist
Moffitt Cancer Center
Tampa, Florida
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-619-H01-P. The activity is available for CE credit through March 1, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Thomasina Morris, RPh, MHA, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Clovis, Dedham Group, GSK, Premier
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Jason J. Bergsbaken, PharmD, MBA, BCOP
Amy L. Indorf, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms